Last reviewed · How we verify
TQB3473
TQB3473 is a small molecule drug that targets the PD-1/PD-L1 pathway.
TQB3473 is a small molecule drug that targets the PD-1/PD-L1 pathway. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | TQB3473 |
|---|---|
| Sponsor | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
| Drug class | PD-1/PD-L1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TQB3473 works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Fatigue
- Diarrhea
- Nausea
Key clinical trials
- A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults (PHASE2)
- A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia (PHASE3)
- A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TQB3473 CI brief — competitive landscape report
- TQB3473 updates RSS · CI watch RSS
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. portfolio CI